Results 81 to 90 of about 58,087 (312)

A critical review of bioactive glasses and glass–ceramics in cancer therapy

International Journal of Applied Glass Science, Volume 14, Issue 1, Page 69-87, January 2023., 2023
Abstract There is an ongoing profound shift in using glass as a primarily passive material to one that instills active properties. We believe and demonstrate that bioactive glasses (BGs) and glass–ceramics (BGCs) as functional biomaterials for cancer therapy can transform the world of healthcare in the 21st century.
Ali Moeini, Turan Hassanzadeh Chinijani, Adrine Malek Khachatourian, Marcus Vinicius Lia Fook, Francesco Baino, Maziar Montazerian   +5 more
wiley   +1 more source

Coded Aperture and Compton Imaging for the Development of $^{225}$Ac-based Radiopharmaceuticals [PDF]

arXiv, 2022
Targeted alpha-particle therapy (TAT) has great promise as a cancer treatment. Arguably the most promising TAT radionuclide that has been proposed is $^{225}$Ac. The development of $^{225}$Ac-based radiopharmaceuticals has been hampered due to the lack of effective means to study the daughter redistribution of these agents in small animals at the ...
arxiv  

Bisphosphonate-induced periprosthetic fracture: a cause of painful total hip arthroplasty [PDF]

, 2014
Background. Cases have been reported in the literature of periprosthetic fractures associated with the use of bisphosphonates occurring in the long term following a Total Hip Replacement (THR).
Bhattacharyya, Rahul, O’Neill, Gavin, Periasamy, Kumar, Spence, Stephanie   +3 more
core   +4 more sources

Possible Impurities in Radiopharmaceuticals and Corresponding Test Methods

Регуляторные исследования и экспертиза лекарственных средств, 2022
The main quality attributes of radiopharmaceuticals that ensure their effectiveness and safety and are unique to their specifications are activity, radionuclide identity, radionuclide purity, and radiochemical purity. The aim of this study was to analyse
G. E. Kodina, A. O. Malysheva, A. A. Larenkov, A. B. Bruskin   +3 more
doaj   +1 more source

Targeted radionuclide therapy frontiers in theranostics [PDF]

Frontiers in Bioscience, 2017
The concept of targeted radionuclide therapy (TRT) relies on the use of injected nuclear medicine as treating agents, targeted at the cellular or molecular level. The growth of the interest in TRT was stimulated by the advances in radionuclide production and labeling as well as by the improvement in the knowledge of appropriate and specific molecular ...
Francesca Gallivanone 1, Mauro Valente 2, 3, 4, 5, Annarita Savi 6, Carla Canevari 6, Isabella Castiglioni 1   +7 more
openaire   +5 more sources

TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah, Daniel A. Arber, Devendra K. Hiwase   +2 more
wiley   +1 more source

Preclinical animal research on therapy dosimetry with dual isotopes [PDF]

, 2011
Preclinical research into radionuclide therapies based on radiation dosimetry will enable the use of any LET-equivalent radionuclide. Radiation dose and dose rate have significant influence on dose effects in the tumour depending on its radiation ...
A Bitar, A Capello, AE Nahum, C Müller, CC Ling, E Malinen, FM Buffa, GR Borst, HB Marcos, JA O'Donoghue, JA O’Donoghue, JF Fowler, JZ Wang, JZ Wang, KS Kolbert, LE Lantry, M Jong de, M Jong de, M Jong de, M Melis, M Melis, MA Keenan, Marion de Jong, Mark W. Konijnenberg, R Suwinski, S Levegrün, S Pauwels, S Verwijnen, S Webb, TC Stephens, TE Hui, TM Behr   +31 more
core   +4 more sources

RADIONUCLIDE IMAGING AND THERAPY OF NEUROENDOCRINE TUMOURS

Journal of Cancer and Allied Specialties, 2015
The incidence and prevalence of neuroendocrine tumours (NETs) are on the rise. Although NETs are a heterogeneous group of tumours, they have some similar properties, for example, that they can concentrate neuroamines and tend to have a high degree of ...
Shaunak Navalkissoor, Gopinath Gnanasegaran   +1 more
doaj   +1 more source

Production Of 11C‐Labeled Amides Via “In‐Loop” 11C‐Carbonylation

Asian Journal of Organic Chemistry, EarlyView.
The current work utilizes carbon‐11 labelled aroyl dimethylaminopyridinium salts in a two‐step in‐loop carbonylative cross‐coupling reaction of aryl halides with [¹¹C]CO yielding a diverse range of carbon‐11 labelled primary benzamides with good to excellent yields.
Tanpreet Kaur, Xia Shao, Allen F. Brooks, Peter J. H. Scott   +3 more
wiley   +1 more source

Treatment options for PNET liver metastases. a systematic review [PDF]

, 2018
Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo, Crovetto, Anna, Debs, Tarek, Mangogna, Livia Maria, Moschetta, Giovanni, Nigri, Giuseppe, Persechino, Raffaello, Petrucciani, Niccolò, Ramacciato, Giovanni   +8 more
core   +1 more source